www.premierhormonebalance.com Contact today via contact form on website. We respond within 6 hours. International clients welcome. Michael Borkin, NMD has been in professional practice since 1981. Considered the “Father of Naturopathic Endocrinology,” he was responsible for establishing the board specialty and authored the first “National Board in Endocrinology for the American Naturopathic Medical Certification & Accreditation Board” in Washington, DC. In 1989 he began development of a transdermal delivery system designed to deliver hormones and nutriceuticals. In 1996, he established “Market Resource International” to market these transdermal formulas to the medical community. Premier Hormone Balance works exclusively with Dr. Borkin to provide your customized solution for hormone balancing and stress-reduction. Premier Hormone Balance partners with a leading laboratory for salivary analysis of hormones and electrolytes, as well as a manufacturer of advanced custom transdermal remedies. Our “Evidence-Based Approach” has proven the efficacy for the use of transdermal hormonal crèmes for the treatment of hormonal imbalances and dysfunctions related to stress. Dr. Borkin is also Research Director of the National Institute of Endocrine Research. In 2000, Dr. Borkin developed a certification program entitled “Natural Approaches to Endocrinology,” which he has taught at campuses throughout the United States. The program allows physicians of all disciplines to study …
Video Rating: 5 / 5
www.SMFProTrader.com Biotech Stock Alert Equity & Options Volume Activity Alert “HGSI” (Human Genome Sciences).HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug “Suicide Rate” Risks. Human Genome Sciences (NASDAQ: HGSI) opened at .00 after trading as high as .50 in “pre market trading”. today, the stock has hit a low of .68 and a high of .24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The “wall street” media hypsters are at it again indicating that the HGSI FDA Panel Review results were “surprising” and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to .48 in pre market trading as the FDA released it’s 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus — Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus …
Video Rating: 5 / 5